TY - JOUR
T1 - Interference by cephalosporins with creatinine measurement by desk-top analyzers
AU - Nanji, A. A.
AU - Poon, R.
AU - Hinberg, I.
PY - 1987/7
Y1 - 1987/7
N2 - We have carried out a study to evaluate the interference by cephalosporins with the measurement of creatinine by desk-top analyzers. The cephalosporins evaluated at concentrations of 0-250 mg/l were cefazolin sodium, cefoxitin sodium, cefotaxime sodium, and ceftazidime pentahydrate. The instruments evaluated were DT60 (Kodak, Rochester, USA), Seralyzer (Ames Division, Miles Laboratories, IN, USA), and Vision (Abbott Labs, Chicago, USA). All studies were done in plasma. None of the cephalosporins showed any interference with the DT60 analyzer. With the Vision and Seralyzer no interference was seen with cefotaxime or cefazolin. With cefazolin an increase of 10-20 μmol/l creatinine was seen for every 20 mg/l of drug; with cefoxitin there was an increase of 50-80 μmol/l of creatinine for every 100 mg/l of drug. Erroneous creatinine values may be found in patients taking cefazolin and cefoxitin and may lead to inappropriate clinical management.
AB - We have carried out a study to evaluate the interference by cephalosporins with the measurement of creatinine by desk-top analyzers. The cephalosporins evaluated at concentrations of 0-250 mg/l were cefazolin sodium, cefoxitin sodium, cefotaxime sodium, and ceftazidime pentahydrate. The instruments evaluated were DT60 (Kodak, Rochester, USA), Seralyzer (Ames Division, Miles Laboratories, IN, USA), and Vision (Abbott Labs, Chicago, USA). All studies were done in plasma. None of the cephalosporins showed any interference with the DT60 analyzer. With the Vision and Seralyzer no interference was seen with cefotaxime or cefazolin. With cefazolin an increase of 10-20 μmol/l creatinine was seen for every 20 mg/l of drug; with cefoxitin there was an increase of 50-80 μmol/l of creatinine for every 100 mg/l of drug. Erroneous creatinine values may be found in patients taking cefazolin and cefoxitin and may lead to inappropriate clinical management.
UR - http://www.scopus.com/inward/record.url?scp=0023616228&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023616228&partnerID=8YFLogxK
U2 - 10.1007/BF00637643
DO - 10.1007/BF00637643
M3 - Article
C2 - 3443149
AN - SCOPUS:0023616228
SN - 0031-6970
VL - 33
SP - 427
EP - 429
JO - European Journal of Clinical Pharmacology
JF - European Journal of Clinical Pharmacology
IS - 4
ER -